CALABASAS, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the pricing of an underwritten public offering of 2,622,950 shares of its common stock at a public offering price of $45.75 per share. The size of the offering was upsized from $100 million to approximately $120 million. In addition, KYTHERA has granted the underwriters a 30-day option to purchase up to an additional 393,442 shares of common stock.
All of the shares in the offering are to be sold by KYTHERA, with expected net proceeds to KYTHERA of approximately $112.2 million, after deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional shares of common stock. The offering is expected to close on or about October 15, 2013, subject to customary closing conditions.
J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers, and representatives of the underwriters for the offering. Leerink Swann LLC is also acting as a joint book-running manager. Cowen and Company, LLC is acting as co-manager.
A registration statement on Form S-1 relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission on October 8, 2013. A preliminary prospectus relating to the offering is included in the registration statement on Form S-1 filed with the SEC, and a final prospectus relating to the offering will be filed with the SEC. Copies of the prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204; or from the offices of BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at email@example.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is currently in late stage clinical trials for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring.
To the extent that statements contained in this press release are not descriptions of historical facts regarding KYTHERA, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and size of the offering, the conditions affecting the capital markets, general economic, industry, or political conditions, and the satisfaction of customary closing conditions related to the proposed public offering. KYTHERA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the prospectus for this offering included as part of the registration statement on Form S-1/A that was filed by KYTHERA on October 7, 2013, and the final prospectus to be filed by KYTHERA, as well as KYTHERA 's Annual Report on Form 10-K for the year ended December 31, 2012 and its other reports filed with the Securities and Exchange Commission.
CONTACT: Investor Contact:
Associate Director, Investor Relations
Tel: (818) 587-4559
Source: KYTHERA Biopharmaceuticals, Inc.
News Provided by Acquire Media